The effect of age and weight on vancomycin serum trough concentrations in pediatric patients

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1264-1272

  Madigan, Theresa ^a   Sieve, Ronald M ^a   Graner, Kevin K ^a   Banerjee, Ritu ^a  

^a MAYO CLINIC   (United States)

Author keywords

age; pediatric; vancomycin; weight

Indexed keywords

VANCOMYCIN;

ADOLESCENT; ADULT; AGE; ARTICLE; BODY WEIGHT; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; WEIGHT GAIN; YOUNG ADULT;

AGE; PEDIATRIC; VANCOMYCIN; WEIGHT;

ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 84900874150     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1331     Document Type: Article

References (32)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
2. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52: 3315-20.
3. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM,. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42: 2398-402.
4. Kullar R, Davis SL, Levine DP, Rybak MJ,. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-81.
5. Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. Oncologist 2012; 17: 1329-36.
6. van Hal SJ, Lodise TP, Paterson DL,. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
7. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
8. Jimenez-Truque N, Thomsen I, Saye E, Creech CB,. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? Pediatr Infect Dis J 2010; 29: 368-70.
9. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
10. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ,. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
11. Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area-under-the-curve exposure. Pediatr Infect Dis J 2013; 32: e155-63.
12. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ,. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28: 398-402.
13. Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B,. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther 2010; 32: 534-42.
14. Silva DC, Seixas GT, Araujo OR, Arduini RG, Carlesse FA, Petrilli AS,. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients. Braz J Infect Dis 2012; 16: 361-5.
15. Moffett BS, Kim S, Edwards MS,. Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila) 2011; 50: 442-6.
16. Miller M, Miller JL, Hagemann TM, Harrison D, Chavez-Bueno S, Johnson PN,. Vancomycin dosage in overweight and obese children. Am J Health Syst Pharm 2011; 68: 2062-8.
17. Broome L, So TY,. An evaluation of initial vancomycin dosing in infants, children, and adolescents. Int J Pediatr 2011; 2011: 470364.
18. Gordon CL, Thompson C, Carapetis JR, Turnidge J, Kilburn C, Currie BJ,. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J 2012; 31: 1269-71.
19. BMI Calculator for Child and Teen. 2012. Available from http://apps.nccd.cdc.gov/dnpabmi/Calculator.aspx?CalculatorType=Metric. Accessed 08 August 2012.
20. Eiland LS, English TM, Eiland EH 3rd,. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 2011; 45: 582-9.
21. Kim DI, Im MS, Choi JH, Lee J, Choi EH, Lee HJ,. Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean J Pediatr 2010; 53: 1000-5.
22. Frymoyer A, Guglielmo BJ, Wilson SD, Scarpace SB, Benet LZ, Hersh AL,. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy 2011; 31: 871-6.
23. Chang D,. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995; 14: 667-73.
24. Chang D, Liem L, Malogolowkin M,. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients. Pediatr Infect Dis J 1994; 13: 969-74.
25. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC,. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 37: 436-40.
26. Grace E,. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother 2012; 67: 1305-10.
27. Ducharme MP, Slaughter RL, Edwards DJ,. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994; 16: 513-8.
28. Bauer LA, Black DJ, Lill JS,. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621-5.
29. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr,. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80.
30. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM,. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA 2010; 303: 242-9.
31. DailyMed. U.S. National Library of Medicine, National Institutes of Health, Health and Human Services. Available from http://dailymed.nlm.nih.gov/ dailymed/lookup.cfm?setid=449c9a41-d61e-49fd-b5e3-d76f74b92acf#nlm34068-7. Accessed 19 November 2012.
32. Friberg LE, Ravva P, Karlsson MO, Liu P,. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012; 56: 3032-42.